|
Volumn 5, Issue , 2008, Pages
|
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABACAVIR PLUS LAMIVUDINE;
AMPRENAVIR PHOSPHATE;
ANTILIPEMIC AGENT;
ANTIRETROVIRUS AGENT;
ATAZANAVIR;
ATORVASTATIN;
CD4 ANTIGEN;
COLESTYRAMINE;
DICLOFENAC;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
GEMFIBROZIL;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
NICOTINIC ACID;
PRAVASTATIN;
RITONAVIR;
TRIACYLGLYCEROL;
VIRUS RNA;
ADULT;
ARTHRALGIA;
ARTICLE;
BILIRUBIN BLOOD LEVEL;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COUGHING;
CREATININE CLEARANCE;
DEPRESSION;
DIARRHEA;
DIZZINESS;
DRUG ERUPTION;
DRUG INDUCED HEADACHE;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
EYE JAUNDICE;
FATIGUE;
FEMALE;
GASTROINTESTINAL DISEASE;
GLOMERULUS FILTRATION RATE;
HERPES ZOSTER;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HYPERBILIRUBINEMIA;
HYPERTRIGLYCERIDEMIA;
HYPOPHOSPHATEMIA;
INSOMNIA;
JAUNDICE;
KIDNEY DYSFUNCTION;
LIVER TOXICITY;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
NAUSEA;
OPEN STUDY;
PARESTHESIA;
PHOSPHATE BLOOD LEVEL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RANK SUM TEST;
RHINOPHARYNGITIS;
SIDE EFFECT;
STATISTICAL ANALYSIS;
SYPHILIS;
TREATMENT FAILURE;
UPPER RESPIRATORY TRACT INFECTION;
|
EID: 43149106498
PISSN: 17426405
EISSN: None
Source Type: Journal
DOI: 10.1186/1742-6405-5-5 Document Type: Article |
Times cited : (92)
|
References (39)
|